Prelude Therapeutics Inc - 10-Q Filing
Prelude Therapeutics reports Q3 2025 financial results including research and development expenses and updates on Incyte Corporation agreements.
Tickers: $PRLD
Prelude Therapeutics reports Q3 2025 financial results including research and development expenses and updates on Incyte Corporation agreements.
Tickers: $PRLD